Jeff Ryckman
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
Jeff Ryckman
May 12, 2024, 07:53 |
Insight
Rahul Gosain: Multidisciplinary approach in treating GISM HCC
Rahul Gosain, Director of Regional Infusion Services at Wilmot Cancer Institute, shared a post on LinkedIn: “GI…
Jan 2, 2024, 15:04 |
Insight
Jeff Ryckman: The Netherlands has consistently produced excellent research on the 'Good, Bad, and Ugly' categories
Jeff Ryckman, Radiation Oncologist and Assistant Professor at West Virginia University, shared a post by…
Dec 28, 2023, 18:20 |
Blog
Jeff Ryckman: Sheets version of the Airtable with 53 ready-to-use site-specific templates
Jeff Ryckman, Assistant Professor, Radiation Oncologist at WVU Medicine Camden Clark Medical Center, recently shared…
Dec 17, 2023, 18:02 |
Insight
Todd Scarbrough: Are ASTRO's radonc partial breast RT guidelines and current NCCN partial breast RT guidelines at odds for breast cancer treatment?
Todd Scarbrough, Radiation Oncologist at Northeast Alabama Regional Medical Center, shared on X: "Are ASTRO's…
Nov 30, 2023, 12:31 |
Insight
Jeff Ryckman: Omitting RT in bulky early-stage cHL
Jeff Ryckman, Radiation Oncologist and Assistant Professor at West Virginia University, shared the following post…
Nov 23, 2023, 16:16 |
Blog
Mark Lewis: Oncology has a PR problem
Mark Lewis shared a post by Jeff Ryckman, Assistant Professor of Radiation Oncology at WVU…
Sep 20, 2023, 17:13 |
Insight
Jeff Ryckman: How many patients make it to CAR-T without ever seeing radiotherapy?
Jeff Ryckman, Radiation Oncologist and Assistant Professor at West Virginia University shared a post by…
All:
7
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube